Immunotherapy
Finding ways to stimulate the body's immune system to help attack cancer cells is a growing area of research at The Institute of Cancer Research.
Clinical trials led by the ICR and our hospital partner The Royal Marsden have shown that the immunotherapy drug pembrolizumab can help extend the lives of some patients with advanced head and neck cancer, and prostate cancer.
The use of 'oncolytic' viruses, which can kill cancer cells both directly and by directing the immune system against them, is also an exciting area of research being explored by ICR researchers.
This page highlights recent news stories, blog posts and videos that concern immunotherapy research at the ICR.
Related pages
Latest ICR News
ICR and life sciences company QBiotics launch new collaboration to study potential cancer drug derived from rainforest tree species
Scientists at The Institute of Cancer Research, London, are collaborating with life sciences company QBiotics to unravel the molecular and cellular mechanisms of a potential new cancer drug.
ICR scientists unveil AI-powered platform that helps researchers speed up biomarker discoveries for personalised cancer treatment
An ICR team has unveiled a cutting-edge research platform powered by artificial intelligence (AI) that will revolutionise cancer research by allowing researchers to integrate and analyse large and complex clinical trial datasets, speeding up the discovery of new cancer biomarkers.